Currently, there are 1.77B common shares owned by the public and among those 1.76B shares have been available to trade.
The company’s stock has a 5-day price change of -2.01% and 14.79% over the past three months. ABBV shares are trading 24.55% year to date (YTD), with the 12-month market performance up to 30.20% higher. It has a 12-month low price of $135.85 and touched a high of $199.95 over the same period. ABBV has an average intraday trading volume of 4.69 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.64%, -0.26%, and 10.32% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Abbvie Inc (NYSE: ABBV) shares accounts for 73.04% of the company’s 1.77B shares outstanding.
It has a market capitalization of $340.92B and a beta (3y monthly) value of 0.62. The stock’s trailing 12-month PE ratio is 64.56, while the earnings-per-share (ttm) stands at $2.99. The company has a PEG of 7.97 and a Quick Ratio of 0.71 with the debt-to-equity ratio at 10.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.29% over the week and 1.68% over the month.
Earnings per share for the fiscal year are expected to decrease by -2.21%, and 11.40% over the next financial year. EPS should grow at an annualized rate of 8.10% over the next five years, compared to -5.77% over the past 5-year period.
Looking at the support for the ABBV, a number of firms have released research notes about the stock. HSBC Securities stated their Buy rating for the stock in a research note on June 05, 2024, with the firm’s price target at $185. Cantor Fitzgerald coverage for the Abbvie Inc (ABBV) stock in a research note released on May 17, 2024 offered a Overweight rating with a price target of $200. Goldman on their part issued Buy rating on December 11, 2023.
